Bone Mineral Density and Quantitative Ultrasound Parameters in Patients with Klinefelter's Syndrome after Long-Term Testosterone Substitution

2001 ◽  
Vol 12 (1) ◽  
pp. 55-62 ◽  
Author(s):  
J. P. W. van den Bergh ◽  
A. R. M. M. Hermus ◽  
A. I. Spruyt ◽  
C. G. J. Sweep ◽  
F. H. M. Corstens ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Quantitative Ultrasound ◽  
Klinefelter’S Syndrome ◽  
Klinefelter's Syndrome ◽  
Mineral Density ◽  
Testosterone Substitution ◽  
Ultrasound Parameters

Klinefelter's syndrome and bone mineral density: Is osteoporosis a constant feature?

2011 ◽  
Vol 72 (1) ◽  
pp. 14-18 ◽  
Author(s):  
S. Hiéronimus ◽  
V. Lussiez ◽  
F. Le Duff ◽  
P. Ferrari ◽  
B. Bständig ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Klinefelter’S Syndrome ◽  
Klinefelter's Syndrome ◽  
Mineral Density ◽  
Constant Feature

Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression

2011 ◽  
Vol 8 (6) ◽  
pp. 485-491 ◽  
Author(s):  
Marco Atteritano ◽  
Antonino Lasco ◽  
Susanna Mazzaferro ◽  
Ida Macrì ◽  
Antonino Catalano ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Metabolism ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Quantitative Ultrasound ◽  
Mineral Density ◽  
Ultrasound Parameters

scholarly journals Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men

1997 ◽  
Vol 82 (8) ◽  
pp. 2386-2390 ◽  
Author(s):  
Hermann M. Behre ◽  
Sabine Kliesch ◽  
Eckhard Leifke ◽  
Thomas M. Link ◽  
Eberhard Nieschlag
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Quantitative Computed Tomography ◽  
First Year ◽  
Mineral Density ◽  
Normal Range ◽  
Testosterone Therapy ◽  
Testosterone Treatment ◽  
Testosterone Substitution

In both men and women, a decrease in bone mineral density (BMD) is a major symptom of hypogonadism. Although the effects of estrogens on osteoporosis in women are well documented, comparatively little is known about the effects of long term testosterone substitution on BMD in hypogonadal men. Therefore, we studied BMD in 72 hypogonadal patients (37 men with primary and 35 men with secondary hypogonadism) under testosterone substitution therapy that continued for up to 16 yr. Thirty-two of these men were also seen before initiation of therapy. At annual intervals, trabecular BMD of the lumbar spine was measured by quantitative computed tomography, a true volumetric and reproducible method for long term serial BMD measurements. Serum levels of testosterone increased to the normal range in all androgen-treated hypogonadal men. The most significant increase in BMD was seen during the first year of testosterone treatment in previously untreated patients, when BMD increased from 95.2 ± 5.9 to 120.0 ± 6.1 mg/cm3 hydroxyapatite (mean ± se). Long term testosterone treatment maintained BMD in the age-dependent reference range in all 72 hypogonadal men, independent of the type of hypogonadism. Transdermal testosterone patches applied to the scrotum were as effective in normalizing BMD as im testosterone enanthate injections. In summary, testosterone therapy increases BMD in hypogonadal men regardless of age. The greatest increase is seen during the first year of treatment in previously untreated patients with low initial BMD. In hypogonadal men, BMD can be normalized and maintained in the normal range by continuous, long term testosterone substitution.

Sign in / Sign up

Export Citation Format

Share Document